Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis

Etelcalcetide is the first intravenous calcimimetic agent authorized for the treatment of secondary hyperparathyroidism (sHPT) in patients undergoing hemodialysis in Europe, the US, and Japan. The relationship between sHPT and diabetes resides on complex, bidirectional effects and largely unknown ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Jianzhen, Deng, Guangrui, Gao, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914547/
https://www.ncbi.nlm.nih.gov/pubmed/29719376
http://dx.doi.org/10.2147/DDDT.S160223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914547/
https://www.ncbi.nlm.nih.gov/pubmed/29719376
http://dx.doi.org/10.2147/DDDT.S160223

Ejemplares similares